The invention provides use of epalrestat in preparation of pancreatic cancer drugs. The pancreatic cancer drugs are used for inhibiting secretion of exosomes from pancreatic cancer cells. The invention also provides a method for verifying the inhibition effect of epalrestat on secretion of exosomes from pancreatic cancer cells. The method includes steps of: extracting cell supernatant exosomes by using a low-temperature ultracentrifugation method; lysing the collected exosomes, then using a BCA kit to quantify the resulting exosomal protein, and using the measured amount of the protein to reflect the amount of the exosomes; using a transmission electron microscope to verify a double-layer lipid membrane wrapped cup-shaped structure of the exosomes; and detecting exosome protein concentration by protein polyacrylamide gel electrophoresis with Coomassie brilliant blue. The invention provides a novel use of epalrestat, namely the inhibition of exosome secretion. The epalrestat has great application potential in clinical tumor treatment.

Some embodiments described herein relate to systems and methods operable to combine immunoassay and Total Protein techniques in a single sample run. Some embodiments described herein allow for multiple sequential immunoassays to be performed in the same microfluidic device. Some embodiments described herein relate to stripping reagents operable to remove primary antibodies associated with immunoassays. Such stripping reagents can allow for additional immunoassays and/or Total Protein assays to be performed on the same sample.

Abstract The disclosure provides a reagent comprising a leuco dye and a compound represented by Formula (I): ##STR00001## where R represents a hydrocarbon chain having 8 to 17 carbon atoms, the reagent for measuring glycoprotein, a kit comprising the reagent and a second reagent, and methods of measuring hemoglobin A1c using the reagent.

Methods for detection and quantitative measurement of proteins with a Coomassie Brilliant Blue Assay with improved sensitivity and maintaining high linearity over a broad measuring range are provided herein. In particular, a method of detecting a protein in a protein-containing sample is provided. The method includes providing a sample including a protein, a reagent including Coomassie Brilliant Blue and having a pH between 0.85 and 1.1, combining the sample and the reagent, and determining absorption at first and second wavelength to determine the amount of protein in the sample. The ratio of the absorption value at the first wavelength between about 580 to 620 nm to the absorption value at the second wavelength between about 520 to 370 nm is used in the spectral photometric determination of the amount of protein.

An object of the present invention is to provide a reagent kit, a measurement kit, and a measurement method for measuring serum amyloid A, which enable simple and rapid measurement of serum amyloid A by promoting dissociation of the serum amyloid A from HDL and carrying out an antigen-antibody reaction. According to the present invention, provided is a reagent kit for measuring serum amyloid A, including first particles having a label and modified with a first binding substance having a property of specifically binding to serum amyloid A, at least one nonionic surfactant having an HLB value of 17 to 20, which is defined by (inorganicity value/organicity value)×10, and a molecular weight of 1000 or less, and a buffer capable of adjusting a pH of a reaction solution to be in a range of 5.5 to 7.0 or a range of 8.5 to 9.0.

Provided herein is a novel screening method for a client protein-protecting protein, and a physiologically active protein-stabilizing protein and a pharmaceutical composition using the protein. Also provided herein is a method for screening for a client protein-protecting protein, including the step of evaluating stability of a client protein in the presence of a protein having an intrinsically disordered structure. Also provided herein is an agent for stabilizing a physiologically active protein comprising, as an active ingredient, a protein having any one of amino acid sequences of SEQ ID NOs: 1 to 6; and a pharmaceutical composition including the protein and a physiologically active protein.

This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

Provided herein is the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. Provided herein are methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

Systems and methods for bacterial load sensing devices are disclosed. An example contamination sensing device may comprise a body, a light emitter disposed on the body and configured to emit an excitation wavelength of light toward a surface, a sensor disposed on the body, configured to detect light, and directed toward the surface, and a filter adjuster configured to determine, based on the excitation wavelength of light, a filter configured to remove light outside of an emission wavelength range, wherein the emission wavelength range corresponds to wavelengths of light emitted by contamination upon exposure to the excitation wavelength of light, and adjustably move the filter in front of the sensor.

Systems and methods for bacterial load sensing devices are disclosed. An example contamination sensing device may comprise a body, a light emitter disposed on the body and configured to emit an excitation wavelength of light toward a surface, a sensor disposed on the body, configured to detect light, and directed toward the surface, and a filter adjuster configured to determine, based on the excitation wavelength of light, a filter configured to remove light outside of an emission wavelength range, wherein the emission wavelength range corresponds to wavelengths of light emitted by contamination upon exposure to the excitation wavelength of light, and adjustably move the filter in front of the sensor.